The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
Open accessAbstract
Middle East respiratory syndrome coronavirus (MERS-CoV) is a lineage C betacoronavirus that since its emergence in 2012 has caused outbreaks in human populations with case-fatality rates of ∼36%. As in other coronaviruses, the spike (S) glycoprotein of MERS-CoV mediates receptor recognition and membrane fusion and is the primary target of the humoral immune response during infection. Here we use structure-based design to develop a generalizable strategy for retaining coronavirus S proteins in the antigenically optimal prefusion conformation and demonstrate that our engineered immunogen is able to elicit high neutralizing antibody titers against MERS-CoV. We also determined high-resolution structures of the trimeric MERS-CoV S ectodomain in complex with G4, a stem-directed neutralizing antibody. The structures reveal that G4 recognizes a glycosylated loop that is variable among coronaviruses and they define four conformational states of the trimer wherein each receptor-binding domain is either tightly packed at the membrane-distal apex or rotated into a receptor-accessible conformation. Our studies suggest a potential mechanism for fusion initiation through sequential receptor-binding events and provide a foundation for the structure-based design of coronavirus vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immune responses are improved by introducing two consecutive proline residues (2P), which are known to retain the full-length S protein in the prefusion conformation.64,65”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [64]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both vaccines encode the same full-length, pre-fusion stabilized severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein13,14 and are encapsulated in lipid nanoparticles (LNPs) with identical composition.”
From Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine (2022) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Stabilizing coronavirus spike proteins by substituting two prolines at the top of heptad repeat 1 prevents structural rearrangements of the fusion (S2) subunit.”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Moreover, S-2P conformational stability translates into greater immunogenicity,27-29 based on preservation of neutralization-sensitive epitopes at the apex of the prefusion molecule, as shown for respiratory syncytial virus F glycoprotein,30 and improved protein expression,27 which is particularly advantageous for gene-based antigen delivery.”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 46,047
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,677
RELION: Implementation of a Bayesian approach to cryo-EM structure determination
Scheres, S. H. W. (2012) · Journal of Structural Biology · doi:10.1016/j.jsb.2012.09.006 · Cited by 5,446
How good are my data and what is the resolution?
Evans, P. R., & Murshudov, G. N. (2013) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444913000061 · Cited by 4,743
Comparative Protein Structure Modeling Using MODELLER
Webb, B., & Šali, A. (2016) · Current Protocols in Bioinformatics · doi:10.1002/cpbi.3 · Cited by 4,404
PHENIX : building new software for automated crystallographic structure determination
Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., & Terwilliger, T. C. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902016657 · Cited by 4,361
Ashkenazy, H., Abadi, S., Martz, E., Chay, O., Mayrose, I., Pupko, T., & Ben-Tal, N. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw408 · Cited by 3,163
Cited by
Sorted by citations
Items 301–400 of 1,000
Biparatopic sybodies neutralize SARS‐CoV‐2 variants of concern and mitigate drug resistance
Walter, J. D., Hutter, C. A. J., Garaeva, A. A., Scherer, M., Zimmermann, I., Wyss, M., Rheinberger, J., Ruedin, Y., Earp, J. C., Egloff, P., et al. (2022) · EMBO Reports · doi:10.15252/embr.202154199 · Cited by 49
Molaei, S., Dadkhah, M., Asghariazar, V., Karami, C., & Safarzadeh, E. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107051 · Cited by 50
Lewis, L. M., Badkar, A. V., Cirelli, D. J., Combs, R. G., & Lerch, T. F. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.09.014 · Cited by 49
Human coronavirus HKU1 recognition of the TMPRSS2 host receptor
McCallum, M., Park, Y., Stewart, C., Sprouse, K. R., Addetia, A., Brown, J. T., Tortorici, M. A., Gibson, C. A., Wong, E., Ieven, M. M., et al. (2024) · Cell · doi:10.1016/j.cell.2024.06.006 · Cited by 51
Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity
Bowman, K. A., Stein, D., Shin, S. A., Ferbas, K. G., Tobin, N. H., Mann, C. J., Fischinger, S., Saphire, E. O., Lauffenburger, D. A., Rimoin, A. W., et al. (2022) · mBio · doi:10.1128/mbio.01647-22 · Cited by 49
mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection
Rauch, S., Gooch, K., Hall, Y., Salguero, F. J., Dennis, M. J., Gleeson, F. V., Harris, D., Ho, C., Humphries, H. E., Longet, S., et al. (2020) · doi:10.1101/2020.12.23.424138 · Cited by 48
Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein
Goo, J., Jeong, Y., Park, Y.-S., Yang, E., Jung, D., Rho, S., Park, U., Sung, H., Park, P., Choi, J., et al. (2020) · Virus Research · doi:10.1016/j.virusres.2020.197863 · Cited by 47
Zhou, T., Tsybovsky, Y., Olia, A. S., Gorman, J., Rapp, M., Cerutti, G., Chuang, G., Katsamba, P. S., Nazzari, A. F., Sampson, J. M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.04.187989 · Cited by 48
Self-citationGagné, M., Moliva, J. I., Foulds, K. E., Andrew, S. F., Flynn, B. J., Werner, A. P., Wagner, D. A., Teng, I., Lin, B. C., Moore, C. A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.03.479037 · Cited by 47
Self-citationStewart-Jones, G., Elbashir, S. M., Wu, K., Lee, D., Renzi, I., Ying, B., Koch, M., Sein, C. E., Choi, A., Whitener, B. M., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf4100 · Cited by 55
Molecular basis of convergent evolution of ACE2 receptor utilization among HKU5 coronaviruses
Park, Y., Liu, C., Lee, J., Brown, J. T., Ma, C., Liu, P., Gen, R., Xiong, Q., Zepeda, S. K., Stewart, C., et al. (2025) · Cell · doi:10.1016/j.cell.2024.12.032 · Cited by 47
Wørzner, K., Sheward, D. J., Schmidt, S., Hanke, L., Zimmermann, J., McInerney, G. M., Hedestam, G. B. K., Murrell, B., Christensen, D., & Pedersen, G. K. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2020.103197 · Cited by 49
Can We AlphaFold Our Way Out of the Next Pandemic?
Higgins, M. K. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167093 · Cited by 48
Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview
Mehra, R., & Kepp, K. P. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00433 · Cited by 45
Broad-spectrum pan-genus and pan-family virus vaccines
Tan, C. W., Valkenburg, S., Poon, L. L. M., & Wang, L. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.05.017 · Cited by 42
Self-citationThe Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template
Andrabi, R., Pallesen, J., Allen, J. D., Song, G., Zhang, J., de Val, N., Gegg, G., Porter, K., Su, C.-Y., Pauthner, M. G., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.082 · Cited by 46
Self-citationMiersch, S., Li, Z., Saberianfar, R., Ustav, M., Case, J. B., Blazer, L. L., Chen, C., Ye, W., Pavlenco, A., Gorelik, M., et al. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167177 · Cited by 45
Profiles of current COVID-19 vaccines
Heinz, F. X., & Stiasny, K. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-021-01835-w · Cited by 45
50 Years of structural immunology
Wilson, I. A., & Stanfield, R. L. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100745 · Cited by 44
van Oosten, L., Altenburg, J. J., Fougeroux, C. E., Geertsema, C., van den End, F., Evers, W. A. C., Westphal, A. H., Lindhoud, S., van den Berg, W., Swarts, D. C., et al. (2021) · mBio · doi:10.1128/mbio.01813-21 · Cited by 43
Akache, B., Renner, T. M., Tran, A., Deschatelets, L., Dudani, R., Harrison, B. A., Duque, D., Haukenfrers, J., Rossotti, M. A., Gaudreault, F., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-01363-7 · Cited by 43
Structure‐guided envelope trimer design in HIV‐1 vaccine development: a narrative review
Derking, R., & Sanders, R. W. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25797 · Cited by 46
Corbett, K. S., Nason, M. C., Flach, B., Gagne, M., O’ Connell, S., Johnston, T. S., Shah, S. N., Edara, V. V., Floyd, K., Lai, L., et al. (2021) · doi:10.1101/2021.04.20.440647 · Cited by 43
Self-citationSong, X., Shi, Y., Ding, W., Niu, T., Sun, L., Tan, Y., Chen, Y., Shi, J., Xiong, Q., Huang, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20401-y · Cited by 42
Conformational flexibility and structural variability of SARS-CoV2 S protein
Pramanick, I., Sengupta, N., Mishra, S., Pandey, S., Girish, N., Das, A., & Dutta, S. (2021) · Structure · doi:10.1016/j.str.2021.04.006 · Cited by 43
ACE2-lentiviral transduction enables mouse SARS-CoV-2 infection and mapping of receptor interactions
Rawle, D. J., Le, T. T., Dumenil, T. D., Yan, K., Tang, B., Nguyen, W., Watterson, D., Modhiran, N., Hobson‐Peters, J., Bishop, C., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009723 · Cited by 41
Fluckiger, A.-C., Ontsouka, B., Bozic, J., Diress, A., Ahmed, T., Berthoud, T. K., Tran, A., Duque, D., Liao, M., McCluskie, M. J., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.07.034 · Cited by 43
Sliepen, K., Radić, L., Capella-Pujol, J., Watanabe, Y., Zon, I., Chumbe, A., Lee, W.-H., de Gast, M., Koopsen, J., Koekkoek, S. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34961-8 · Cited by 43
Self-citationRiley, T. P., Chou, H., Hu, R., Bzymek, K. P., Correia, A. R., Partin, A. C., Li, D., Gong, D., Wang, Z., Yu, X., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660198 · Cited by 43
Merkuleva, I. A., Щербаков, Д. Н., Borgoyakova, M. B., Васильевич, Ш. Д., Рудометов, А. П., Карпенко, Л. И., Belenkaya, S. V., Исаева, А. А., Nesmeyanova, V. S., Kazachinskaia, E. I., et al. (2022) · Vaccines · doi:10.3390/vaccines10010096 · Cited by 41
Holmes, E. C., Krammer, F., & Goodrum, F. D. (2024) · Cell · doi:10.1016/j.cell.2024.07.025 · Cited by 46
Li, H., Zhang, Y., Li, D., Deng, Y., Xu, H., Zhao, C., Liu, J., Wen, D., Zhao, J., Li, Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00797-9 · Cited by 41
Amanat, F., Thapa, M., Lei, T., Ahmed, S. M. S., Adelsberg, D. C., Carreño, J. M., Strohmeier, S., Schmitz, A. J., Zafar, S., Zhou, J. Q., et al. (2021) · medRxiv · doi:10.1101/2021.03.07.21253098 · Cited by 41
Queirós-Reis, L., da Silva, P. G., Gonçalves, J., Brancale, A., Bassetto, M., & Mesquita, J. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910836 · Cited by 40
Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge
Hsieh, C., Leist, S. R., Miller, E. H., Zhou, L., Powers, J. M., Tse, A. L., Wang, A., West, A., Zweigart, M. R., Schisler, J. C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45404-x · Cited by 43
Self-citationOberemok, V. V., Laikova, K. V., Yurchenko, K. A., Marochkin, N. A., Фомочкина, И. И., & Kubyshkin, A. V. (2020) · Inflammation Research · doi:10.1007/s00011-020-01377-3 · Cited by 39
Biomedical Science to Tackle the COVID-19 Pandemic: Current Status and Future Perspectives
Zamora‐Ledezma, C., Clavijo-Calderón, D., Medina, E. A., Sinche, F. L., Vispo, N. S., Dahoumane, S. A., & Alexis, F. (2020) · Molecules · doi:10.3390/molecules25204620 · Cited by 39
Leveraging deep learning to improve vaccine design
Hederman, A. P., & Ackerman, M. E. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.03.002 · Cited by 41
High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike
Tan, T. J. C., Mou, Z., Lei, R., Ouyang, W. O., Yuan, M., Song, G., Andrabi, R., Wilson, I. A., Kieffer, C., Dai, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37786-1 · Cited by 40
Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies
de la Peña, A. T., & Sanders, R. W. (2018) · Retrovirology · doi:10.1186/s12977-018-0445-y · Cited by 41
Lee, P., Kim, C.-U., Seo, S. H., & Kim, D. (2021) · Immune Network · doi:10.4110/in.2021.21.e4 · Cited by 40
Li, G., Wang, A., Chen, Y., Sun, Y., Du, Y., Wang, X., Ding, P., Jia, R., Wang, Y., & Zhang, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.635677 · Cited by 41
Advanced Materials for SARS‐CoV‐2 Vaccines
Mabrouk, M. T., Huang, W., Martínez‐Sobrido, L., & Lovell, J. F. (2021) · Advanced Materials · doi:10.1002/adma.202107781 · Cited by 38
Strohl, W. R., Ku, Z., An, Z., Carroll, S. F., Keyt, B. A., & Strohl, L. M. (2022) · BioDrugs · doi:10.1007/s40259-022-00529-7 · Cited by 35
Zhong, L., Zhang, W., Krummenacher, C., Chen, Y., Zheng, Q., Zhao, Q., Zeng, M., Xia, N., Zeng, Y., Xu, M., et al. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2023.03.001 · Cited by 37
Elkashif, A., Alhashimi, M., Sayedahmed, E. E., Sambhara, S. R., & Mittal, S. K. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1345 · Cited by 41
Kahlout, R. A. A., Nasrallah, G. K., Farag, E., Wang, L., Lattwein, E., Müller, M. A., Zowalaty, M. E. E., Al‐Romaihi, H. E., Graham, B. S., Thani, A. A. A., et al. (2019) · Journal of Immunology Research · doi:10.1155/2019/1386740 · Cited by 38
Self-citationOu, X., Xu, G. Z., Li, P., Liu, Y., Zan, F., Liu, P., Hu, J., Lu, X., Dong, S., Zhou, Y., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00581-9 · Cited by 35
(2024) · doi:10.1073/pnas.2404250121 · Cited by 37
Self-citationSimulation-driven design of stabilized SARS-CoV-2 spike S2 immunogens
Nuqui, X., Casalino, L., Zhou, L., Shehata, M., Wang, A., Tse, A. L., Ojha, A. A., Kearns, F. L., Rosenfeld, M. A., Miller, E. H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50976-9 · Cited by 33
Self-citationLiu, Z., Xu, W., Chen, Z., Fu, W., Zhan, W., Gao, Y., Zhou, J., Zhou, Y., Wu, J., Wang, Q., et al. (2021) · Protein & Cell · doi:10.1007/s13238-021-00871-6 · Cited by 38
Tall tails: cryo-electron microscopy of phage tail DNA ejection conduits
Hardy, J. M., Dunstan, R. A., Lithgow, T. J., & Coulibaly, F. (2022) · Biochemical Society Transactions · doi:10.1042/bst20210799 · Cited by 36
The use of databases, data mining and immunoinformatics in vaccinology: where are we?
Hegde, N. R., Gauthami, S., Kumar, H. M. S., & Bayry, J. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1413088 · Cited by 38
Veit, S., Jany, S., Fux, R., Sutter, G., & Volz, A. (2018) · Viruses · doi:10.3390/v10120718 · Cited by 37
Bharath, B. R., Damle, H., Ganju, S., & Damle, L. (2020) · F1000Research · doi:10.12688/f1000research.24143.1 · Cited by 35
Yang, Y., Shi, W., Abiona, O. M., Nazzari, A. F., Olia, A. S., Ou, L., Phung, E., Stephens, T., Tsybovsky, Y., Verardi, R., et al. (2021) · Vaccines · doi:10.3390/vaccines9020073 · Cited by 36
Self-citationTargovnik, A. M., Simonin, J. A., Callum, G. J. M., Smith, I., Warlet, F. U. C., Nugnes, M. V., Miranda, M. V., & Belaich, M. N. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11615-1 · Cited by 34
VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants
Prates-Syed, W. A., Chaves, L. C. S., Crema, K. P., Vuitika, L., Lira, A. A. D. L., Côrtes, N., Kersten, V., Guimarães, F. E. G., Sadraeian, M., da Silva, F. L. B., et al. (2021) · Vaccines · doi:10.3390/vaccines9121409 · Cited by 36
Braet, S. M., Buckley, T. S., Venkatakrishnan, V., Dam, K.-M. A., Björkman, P. J., & Anand, G. S. (2023) · eLife · doi:10.7554/elife.82584 · Cited by 36
Pierce, B. G., Keck, Z., Wang, R., Lau, P., Garagusi, K., Elkholy, K. H., Toth, E. A., Urbanowicz, R. A., Guest, J. D., Agnihotri, P., et al. (2020) · Journal of Virology · doi:10.1128/jvi.00704-20 · Cited by 34
The rapidly evolving role of cryo-EM in drug design
Wigge, C., Stefanovic, A., & Radjainia, M. (2020) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2020.12.003 · Cited by 33
Hawman, D. W., Meade-White, K. D., Archer, J. F., Leventhal, S. S., Wilson, D., Shaia, C., Randall, S., Khandhar, A. P., Krieger, K., Hsiang, T.-Y., et al. (2022) · eLife · doi:10.7554/elife.75537 · Cited by 34
Francica, J., Flynn, B., Foulds, K., Noe, A. T., Werner, A. P., Moore, I. N., Gagne, M., Johnston, T., Tucker, C., Davis, R. L., et al. (2021) · bioRxiv · doi:10.1101/2021.03.02.433390 · Cited by 35
Self-citationAn FcRn-targeted mucosal vaccine against SARS-CoV-2 infection and transmission
Li, W., Wang, T., Rajendrakumar, A. M., Acharya, G., Miao, Z., Varghese, B. P., Yu, H., Dhakal, B., LeRoith, T., Karunakaran, A. C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42796-0 · Cited by 33
The sprint to solve coronavirus protein structures — and disarm them with drugs
Scudellari, M. (2020) · Nature · doi:10.1038/d41586-020-01444-z · Cited by 32
Guan, H., Wang, Y., Perčulija, V., Saeed, A. F. U. H., Liu, Y., Li, J., Jan, S. S., Li, Y., Zhu, P., & Ouyang, S. (2020) · Journal of Virology · doi:10.1128/jvi.01301-20 · Cited by 34
Requena, D., Médico, A., Chacón, R. D., Ramírez, M., & Marín-Sánchez, O. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02008 · Cited by 34
Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2
Zhu, L., Deng, Y., Zhang, R.-R., Cui, Z., Sun, C.-Y., Fan, C., Xing, X., Huang, W., Chen, Q., Zhang, N.-N., et al. (2020) · National Science Review · doi:10.1093/nsr/nwaa297 · Cited by 34
Self-citationMuhammed, Y., Nadabo, A. Y., Pius, M., Sani, B. E., Usman, J., Garba, N. A., Mohammed, J. S., Olayanju, B., Bala, S. Z., Abdullahi, M. G., et al. (2021) · Biosafety and Health · doi:10.1016/j.bsheal.2021.07.003 · Cited by 33
Lanini, S., Capone, S., Antinori, A., Milleri, S., Nicastri, E., Camerini, R., Agrati, C., Castilletti, C., Mori, F., Sacchi, A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj1996 · Cited by 34
Bassi, J., Giannini, O., Silacci-Fregni, C., Pertusini, L., Hitz, P., Terrot, T., Franzosi, Y., Muoio, F., Saliba, C., Meury, M., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263328 · Cited by 33
Large-scale design and refinement of stable proteins using sequence-only models
Singer, J. M., Novotney, S., Strickland, D., Haddox, H. K., Leiby, N., Rocklin, G. J., Chow, C. M., Roy, A., Bera, A. K., Motta, F. C., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265020 · Cited by 34
Production and secretion of functional SARS-CoV-2 spike protein in Chlamydomonas reinhardtii
Kiefer, A. M., Niemeyer, J., Probst, A., Erkel, G., & Schroda, M. (2022) · Frontiers in Plant Science · doi:10.3389/fpls.2022.988870 · Cited by 37
Prompetchara, E., Ketloy, C., Alameh, M., Tharakhet, K., Kaewpang, P., Yostrerat, N., Pitakpolrat, P., Buranapraditkun, S., Manopwisedjaroen, S., Thitithanyanont, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37795-0 · Cited by 31
Structure and design of Langya virus glycoprotein antigens
Wang, Z., McCallum, M., Yan, L., Gibson, C. A., Sharkey, W., Park, Y.-J., Dang, H. V., Amaya, M., Person, A., Broder, C. C., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2314990121 · Cited by 32
Liu, H., Zhou, C., An, J., Song, Y., Yü, P., Li, J., Gu, C., Hu, D., Jiang, Y., Zhang, L., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.10.066 · Cited by 32
mRNA COVID-19 Vaccines—Facts and Hypotheses on Fragmentation and Encapsulation
Jacques Demongeot, A., & Fougère, C. (2022) · Vaccines · doi:10.3390/vaccines11010040 · Cited by 36
Kawase, M., Kataoka, M., Shirato, K., & Matsuyama, S. (2019) · Journal of Virology · doi:10.1128/jvi.00785-19 · Cited by 32
Coronavirus in human diseases: Mechanisms and advances in clinical treatment
Lin, P., Wang, M., Wei, Y., Kim, T., & Wei, X. (2020) · MedComm · doi:10.1002/mco2.26 · Cited by 32
Seroprevalence of SARS-CoV-2 Antibodies in Children and Adults in St. Louis, Missouri, USA
Smith, B. K., Janowski, A. B., Danis, J. E., Harvey, I. B., Zhao, H., Dai, Y.-N., Farnsworth, C. W., Gronowski, A. M., Roper, S. M., Fremont, D. H., et al. (2021) · mSphere · doi:10.1128/msphere.01207-20 · Cited by 31
Rapid Development of Analytical Methods for Evaluating Pandemic Vaccines: A Covid-19 Perspective
Baldwin, J., Piplani, S., Sakala, I. G., Honda‐Okubo, Y., Li, L., & Petrovsky, N. (2021) · Bioanalysis · doi:10.4155/bio-2021-0096 · Cited by 33
Wang, J., Yin, X., Wen, Y., Lu, J. L., Zhang, R., Zhou, S., Liao, C.-M., Wei, H.-W., & Guo, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02025 · Cited by 31
Parzych, E. M., Du, J., Ali, A., Schultheis, K., Frase, D. M., Smith, T. R. F., Cui, J., Chokkalingam, N., Tursi, N. J., Andrade, V. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33309-6 · Cited by 30
Self-citationzu Natrup, C. M., Tscherne, A., Dahlke, C., Ciurkiewicz, M., Shin, D., Fathi, A., Rohde, C., Kalodimou, G., Halwe, S., Limpinsel, L., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159895 · Cited by 32
Ferrari, D., Clementi, N., Criscuolo, E., Ambrosi, A., Corea, F., Resta, C. D., Tomaiuolo, R., Mancini, N., Locatelli, M., Plebani, M., et al. (2021) · Vaccines · doi:10.3390/vaccines9111357 · Cited by 31
A MERS-CoV antibody neutralizes a pre-emerging group 2c bat coronavirus
Tse, L. V., Hou, Y. J., McFadden, E., Lee, R. E., Scobey, T., Leist, S. R., Martinez, D. R., Meganck, R. M., Schäfer, A., Yount, B. L., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg5567 · Cited by 31
Self-citationLuo, X., McAndrews, K. M., Arian, K. A., Morse, S. J., Boeker, V., Kumbhar, S. V., Hu, Y., Mahadevan, K. K., Church, K. A., Chitta, S., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.017 · Cited by 30
Combining structure and genomics to understand antimicrobial resistance
Tunstall, T., Portelli, S., Phelan, J. E., Clark, T. G., Ascher, D. B., & Furnham, N. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.10.017 · Cited by 33
Ghodake, G. S., Shinde, S. K., Kadam, A. A., Saratale, R. G., Saratale, G. D., Syed, A., Elgorban, A. M., Marraiki, N., & Kim, D.-Y. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.112969 · Cited by 31
Current progress and challenges in the design and development of a successful COVID-19 vaccine
Li, T., Zhang, T., Gu, Y., Li, S., & Xia, N. (2021) · Fundamental Research · doi:10.1016/j.fmre.2021.01.011 · Cited by 30
Tsoi, K. K. F., Sung, J. J. �., Lee, H. W. Y., Yiu, K. K. L., Fung, H., & Wong, S. Y. S. (2021) · BMJ Innovations · doi:10.1136/bmjinnov-2021-000661 · Cited by 29
Li, Y., Wang, T., Zhang, J., Shao, B., Gong, H., Wang, Y., He, X., Liu, S., & Liu, T. (2021) · Advanced Theory and Simulations · doi:10.1002/adts.202100152 · Cited by 29
Salazar–García, M., Acosta-Contreras, S., Martinez, G. R., Cruz‐Rangel, A., Flores-Alanis, A., Patiño‐López, G., & Luna-Pineda, V. M. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.817200 · Cited by 29
Pérez, P., Lázaro-Frías, A., Zamora, C., Sánchez‐Cordón, P. J., Astorgano, D., Luczkowiak, J., Delgado, R. B., Casasnovas, J. M., Estéban, M., & García‐Arriaza, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.824728 · Cited by 30
Stark, F. C., Akache, B., Deschatelets, L., Tran, A., Stuible, M., Durocher, Y., McCluskie, M. J., Agbayani, G., Dudani, R., Harrison, B. A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-13819-5 · Cited by 32
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variantsPreprint
Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G. D., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Vilardo, A. E., Edelstein, A., Perandones, C., et al. (2021) · medRxiv · doi:10.1101/2021.03.31.21254660 · Cited by 30
Structural understanding of SARS-CoV-2 virus entry to host cells
Le, K. P. U., Kannappan, S., Kim, T., Lee, J. H., Lee, H.-R., & Kim, K. K. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1288686 · Cited by 34
Structure-based immunogen design — leading the way to the new age of precision vaccines
Sesterhenn, F., Bonet, J., & Correia, B. E. (2018) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2018.06.002 · Cited by 27
Adu-Agyeiwaah, Y., Grant, M. B., & Obukhov, A. G. (2020) · Cells · doi:10.3390/cells9112528 · Cited by 29
SARS-CoV-2, Early Entry Events
CHAMBERS, J. K., Yu, J., Valdés, J. J., & Arulanandam, B. P. (2020) · Journal of Pathogens · doi:10.1155/2020/9238696 · Cited by 32
Metadata
- Authors
- Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., Kong, W.-P., Andres, E. L., Kettenbach, A. N., Denison, M. R., Chappell, J. D., Graham, B. S., Ward, A. B., & McLellan, J. S.
- Affiliations
- Scripps Research Institute (US)
- Dartmouth College (US)
- National Institute of Allergy and Infectious Diseases (US)
- Vanderbilt University Medical Center (US)
- Vanderbilt University (US)
- Corresponding author
- Pallesen, Jesper
- Wang, Nianshuang
- Corbett, Kizzmekia S.
- Ward, Andrew B.
- McLellan, Jason S.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2017-08-14
- Volume
- 114
- Issue
- 35
- Pages
- E7348-E7357
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC5584442
- OpenAlex
- W2750464792
- Cited by
- 1,073
- References
- 89
- Citations by year
- 2026: 48 · 2025: 75 · 2024: 98 · 2023: 127 · 2022: 174 · 2021: 275 · 2020: 220 · 2019: 31 · 2018: 17 · 2017: 6
- FWCI
- 57.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- Funders
- HHS | NIH | National Institute of Allergy and Infectious Diseases (R01AI127521)
- HHS | NIH | National Institute of General Medical Sciences (P20GM113132)
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases (AI005125)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- MERS-CoV, spike protein, structure-based vaccine design, neutralizing antibodies, receptor binding domain, receptor recognition, membrane fusion mechanism, coronavirus vaccines
- MeSH terms
- Animals, Antibodies, Viral, Coronaviridae, Humans, Immunoglobulin G, Mice, Inbred BALB C, Protein Binding, Protein Conformation, Receptors, Virus, Structure-Activity Relationship, Vaccination, Viral Vaccines, Coronavirus Infections, Crystallography, X-Ray, Immunity, Humoral, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus, Middle East Respiratory Syndrome Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
